To the Editor:Lung cancer is characterized by its high incidence and mortality rates,imposing a significant burden of disease globally.[1]Liver metastasis is associated with poorer clinical outcomes and shorter life e...To the Editor:Lung cancer is characterized by its high incidence and mortality rates,imposing a significant burden of disease globally.[1]Liver metastasis is associated with poorer clinical outcomes and shorter life expectancy in non-small cell lung cancer(NSCLC).[2]Although immune checkpoint inhibitors(ICIs)have revolutionized the treatment of NSCLC,existing predictive and prognostic biomarkers have limited effectiveness and pose a clinical challenge,particularly for patients with liver metastasis.展开更多
基金financially supported by the National Natural Science Foundation of China(Nos.82222048 and 82003206)the Natural Science Foundation of Hunan Province(No.2021RC3118).
文摘To the Editor:Lung cancer is characterized by its high incidence and mortality rates,imposing a significant burden of disease globally.[1]Liver metastasis is associated with poorer clinical outcomes and shorter life expectancy in non-small cell lung cancer(NSCLC).[2]Although immune checkpoint inhibitors(ICIs)have revolutionized the treatment of NSCLC,existing predictive and prognostic biomarkers have limited effectiveness and pose a clinical challenge,particularly for patients with liver metastasis.
